CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the business's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $74.54, for a total transaction of $74,540.00. Following the transaction, the director owned 1,000 shares in the company, valued at $74,540. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
CG Oncology Price Performance
CGON stock opened at $76.29 on Wednesday. CG Oncology, Inc. has a 1 year low of $24.85 and a 1 year high of $79.39. The company has a market cap of $6.76 billion, a P/E ratio of -28.36 and a beta of 0.23. The firm has a 50-day moving average of $69.99 and a 200 day moving average of $65.07.
CG Oncology (NASDAQ:CGON - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.24). CG Oncology had a negative net margin of 3,602.68% and a negative return on equity of 25.20%. The firm had revenue of $1.16 million for the quarter, compared to the consensus estimate of $0.36 million. On average, equities research analysts expect that CG Oncology, Inc. will post -3.25 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC bought a new stake in CG Oncology in the first quarter worth $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of CG Oncology by 18.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company's stock valued at $876,000 after acquiring an additional 5,442 shares in the last quarter. Millennium Management LLC raised its position in shares of CG Oncology by 139.4% in the 1st quarter. Millennium Management LLC now owns 596,056 shares of the company's stock worth $14,597,000 after purchasing an additional 347,055 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in CG Oncology by 42.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company's stock worth $4,393,000 after purchasing an additional 53,461 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in CG Oncology by 12.3% in the 2nd quarter. Legal & General Group Plc now owns 44,354 shares of the company's stock worth $1,153,000 after purchasing an additional 4,847 shares in the last quarter. Institutional investors own 26.56% of the company's stock.
Wall Street Analyst Weigh In
CGON has been the topic of several research reports. Wall Street Zen lowered CG Oncology from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Piper Sandler increased their price objective on CG Oncology from $82.00 to $85.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Wolfe Research began coverage on CG Oncology in a research report on Tuesday, May 19th. They set a "peer perform" rating for the company. Truist Financial boosted their target price on shares of CG Oncology from $82.00 to $85.00 and gave the company a "buy" rating in a report on Friday, August 7th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $100.00 target price on shares of CG Oncology in a research report on Wednesday, July 29th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $83.18.
Read Our Latest Research Report on CGON
About CG Oncology
(
Get Free Report)
CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.
Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
